Swiss Pharma Contract

Overview of the transaction:

  • Novartis Venture Fund was an early investor in Swiss Pharma Contract, holding the investment for approximately 10 years. In addition, the founders were seeking a retirement plan.
  • Swiss Pharma Contact was a Phase I CRO based in Basel Switzerland
  • Novartis wished a party to build a process for the sale of the company

Jina Ventures' Role:

  • Jina worked with Novartis Venture Fund and the Company's founders to identify market opportunities
  • The asset was eventually sold to Covance Inc, a global leading CRO organization based in Princeton NJ